Referências
Principais artigos
American Diabetes Association. Standards of care in diabetes - 2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S1-291.Texto completo
Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.Texto completo Resumo
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019 Jun 18;139(25):e1082-143.Texto completo Resumo
American Diabetes Association. Standards of medical care in diabetes - 2022. Diabetes Care. 2022 Jan;45(Suppl 1):S1-264.Texto completo
Writing Committee Members; Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022 Jan 18;79(2):e21-129.Texto completo Resumo
Artigos de referência
1. International Diabetes Federation. IDF diabetes atlas. 10th ed. Brussels, Belgium: International Diabetes Federation; 2021.Texto completo
2. International Diabetes Federation. Diabetes and cardiovascular disease. Brussels, Belgium: International Diabetes Federation; 2016.Texto completo
3. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. Lancet. 2016 Apr 6;387(10027):1513-30.Texto completo Resumo
4. Centers for Disease Control and Prevention. Prevalence of both diagnosed and undiagnosed diabetes. December 2021 [internet publication].Texto completo
5. Akter S, Rahman MM, Abe SK, et al. Prevalence of diabetes and prediabetes and their risk factors among Bangladeshi adults: a nationwide survey. Bull World Health Organ. 2014 Mar 1;92(3):204-13, 213A.Texto completo Resumo
6. Standl E, Khunti K, Hansen TB, et al. The global epidemics of diabetes in the 21st century: current situation and perspectives. Eur J Prev Cardiol. 2019 Dec;26(2 Suppl):7-14.Texto completo Resumo
7. Marx N, Federici M, Schütt K, et al. 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023 Oct 14;44(39):4043-140.Texto completo Resumo
8. Gyldenkerne C, Kahlert J, Olesen KKW, et al. Twenty-year temporal trends in risk of ischemic stroke in incident type 2 diabetes: a Danish population-based cohort study. Diabetes Care. 2022 Sep 1;45(9):2144-51.Texto completo Resumo
9. Leon BM, Maddox TM. Diabetes and cardiovascular disease: epidemiology, biological mechanisms, treatment recommendations and future research. World J Diabetes. 2015 Oct 10;6(13):1246-58.Texto completo Resumo
10. Rawshani A, Rawshani A, Franzén S, et al. Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med. 2017 Apr 13;376(15):1407-18.Texto completo Resumo
11. Gyldenkerne C, Knudsen JS, Olesen KKW, et al. Nationwide trends in cardiac risk and mortality in patients with incident type 2 diabetes: a Danish cohort study. Diabetes Care. 2021 Aug 11 [Epub ahead of print]. Resumo
12. de Ferranti SD, de Boer IH, Fonseca V, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Circulation. 2014 Aug 11;130(13):1110-30.Texto completo Resumo
13. Harjutsalo V, Pongrac Barlovic D, Groop PH. Long-term population-based trends in the incidence of cardiovascular disease in individuals with type 1 diabetes from Finland: a retrospective, nationwide, cohort study. Lancet Diabetes Endocrinol. 2021 Sep;9(9):575-85. Resumo
14. Harjutsalo V, Barlovic DP, Gordin D, et al. Presence and determinants of cardiovascular disease and mortality in individuals with type 1 diabetes of long duration: the FinnDiane 50 years of diabetes study. Diabetes Care. 2021 Aug;44(8):1885-93.Texto completo Resumo
15. Grundy SM, Howard B, Smith S Jr, et al. Prevention conference VI: diabetes and cardiovascular disease. Executive summary: conference proceeding for healthcare professionals from a special writing group of the American Heart Association. Circulation. 2002 May 7;105(18):2231-9.Texto completo Resumo
16. Eckel RH, Wassef M, Chait A, et al. Prevention conference VI: diabetes and cardiovascular disease. Writing Group II: pathogenesis of atherosclerosis in diabetes. Circulation. 2002 May 7;105(18):e138-43.Texto completo Resumo
17. Ndumele CE, Rangaswami J, Chow SL, et al. Cardiovascular-kidney-metabolic health: a presidential advisory from the American Heart Association. Circulation. 2023 Nov 14;148(20):1606-35.Texto completo Resumo
18. Khan SS, Coresh J, Pencina MJ, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: a scientific statement from the American Heart Association. Circulation. 2023 Dec 12;148(24):1982-2004.Texto completo Resumo
19. Joseph JJ, Deedwania P, Acharya T, et al. Comprehensive management of cardiovascular risk factors for adults with type 2 diabetes: a scientific statement from the American Heart Association. Circulation. 2022 Mar;145(9):e722-59.Texto completo Resumo
20. Campagna D, Alamo A, Di Pino A, et al. Smoking and diabetes: dangerous liaisons and confusing relationships. Diabetol Metab Syndr. 2019 Oct 24;11:85.Texto completo Resumo
21. Egede LE, Zheng D. Modifiable cardiovascular risk factors in adults with diabetes: prevalence and missed opportunities for physician counseling. Arch Intern Med. 2002 Feb 25;162(4):427-33.Texto completo Resumo
22. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ. 1998 Mar 14;316(7134):823-8.Texto completo Resumo
23. Arauz-Pacheco C, Parrott MA, Raskin P. The treatment of hypertension in adult patients with diabetes. Diabetes Care. 2002 Jan;25(1):134-47.Texto completo Resumo
24. MacMahon S. Antihypertensive drug treatment: the potential, expected and observed effects on vascular disease. J Hypertens Suppl. 1990 Dec;8(7):S239-44. Resumo
25. Cushman WC, Evans GW, Byington RP, et al; ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85.Texto completo Resumo
26. Wright JT Jr, Williamson JD, Whelton PK, et al; SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015 Nov 26;373(22):2103-16.Texto completo Resumo
27. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998 Sep 12;317(7160):703-13.Texto completo Resumo
28. American Diabetes Association. Standards of care in diabetes - 2023. Diabetes Care. 2023 Jan 1;46(Suppl 1):S1-291.Texto completo
29. Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018 May 15;71(19):e127-248.Texto completo Resumo
30. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan-2022 update. Endocr Pract. 2022 Oct;28(10):923-1049.Texto completo Resumo
31. Kane JP, Pullinger CR, Goldfine ID, et al. Dyslipidemia and diabetes mellitus: role of lipoprotein species and interrelated pathways of lipid metabolism in diabetes mellitus. Curr Opin Pharmacol. 2021 Dec;61:21-7.Texto completo Resumo
32. Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care. 1998 Jan;21(1):160-78. Resumo
33. Bancks MP, Ning H, Allen NB, et al. Long-term absolute risk for cardiovascular disease stratified by fasting glucose level. Diabetes Care. 2019 Jan 7;42(3):457-65. Resumo
34. Skyler JS, Bergenstal R, Bonow RO, et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care. 2009 Jan;32(1):187-92.Texto completo Resumo
35. Wahid A, Manek N, Nichols M, et al. Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. J Am Heart Assoc. 2016 Sep 14;5(9):e002495.Texto completo Resumo
36. Vasankari V, Husu P, Vähä-Ypyä H, et al. Association of objectively measured sedentary behaviour and physical activity with cardiovascular disease risk. Eur J Prev Cardiol. 2017 Aug;24(12):1311-8.Texto completo Resumo
37. Colberg SR, Sigal RJ, Yardley JE, et al. Physical activity/exercise and diabetes: a position statement of the American Diabetes Association. Diabetes Care. 2016 Nov;39(11):2065-79.Texto completo Resumo
38. Cassidy S, Thoma C, Hallsworth K, et al. High intensity intermittent exercise improves cardiac structure and function and reduces liver fat in patients with type 2 diabetes: a randomised controlled trial. Diabetologia. 2016 Jan;59(1):56-66.Texto completo Resumo
39. Bhupathiraju SN, Hu FB. Epidemiology of obesity and diabetes and their cardiovascular complications. Circ Res. 2016 May 27;118(11):1723-35.Texto completo Resumo
40. Van der Schueren B, Ellis D, Faradji RN, et al. Obesity in people living with type 1 diabetes. Lancet Diabetes Endocrinol. 2021 Nov;9(11):776-85. Resumo
41. Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease. Circulation. 2019 Sep 10;140(11):e596-646.Texto completo Resumo
42. Gerstein HC, Mann JF, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001 Jul 25;286(4):421-6.Texto completo Resumo
43. Wachtell K, Ibsen H, Olsen MH, et al. Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med. 2003 Dec 2;139(11):901-6. Resumo
44. Fangel MV, Nielsen PB, Kristensen JK, et al. Albuminuria and risk of cardiovascular events and mortality in a general population of patients with type 2 diabetes without cardiovascular disease: a Danish cohort study. Am J Med. 2020 Jun;133(6):e269-79. Resumo
45. Schulze MB, Rimm EB, Li T, et al. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004 Apr;27(4):889-94.Texto completo Resumo
46. Jeong H, Baek SY, Kim SW, et al. C reactive protein level as a marker for dyslipidaemia, diabetes and metabolic syndrome: results from the Korea National Health and Nutrition Examination Survey. BMJ Open. 2019 Aug 30;9(8):e029861.Texto completo Resumo
47. Hayfron-Benjamin CF, Maitland-van der Zee AH, van den Born BJ, et al. Association between C reactive protein and microvascular and macrovascular dysfunction in sub-Saharan Africans with and without diabetes: the RODAM study. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e001235.Texto completo Resumo
48. Huxley RR, Peters SA, Mishra GD, et al. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015 Mar;3(3):198-206. Resumo
49. Wang H, Ba Y, Cai RC, et al. Association between diabetes mellitus and the risk for major cardiovascular outcomes and all-cause mortality in women compared with men: a meta-analysis of prospective cohort studies. BMJ Open. 2019 Jul 17;9(7):e024935.Texto completo Resumo
50. Xu G, You D, Wong L, et al. Risk of all-cause and CHD mortality in women versus men with type 2 diabetes: a systematic review and meta-analysis. Eur J Endocrinol. 2019 Apr;180(4):243-55.Texto completo Resumo
51. Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014 Aug;57(8):1542-51.Texto completo Resumo
52. Ohkuma T, Komorita Y, Peters SAE, et al. Diabetes as a risk factor for heart failure in women and men: a systematic review and meta-analysis of 47 cohorts including 12 million individuals. Diabetologia. 2019 Sep;62(9):1550-60.Texto completo Resumo
53. Vogel B, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet. 2021 Jun 19;397(10292):2385-438. Resumo
54. Yoshida Y, Chen Z, Baudier RL, et al. Early menopause and cardiovascular disease risk in women with or without type 2 diabetes: a pooled analysis of 9,374 postmenopausal women. Diabetes Care. 2021 Nov;44(11):2564-72.Texto completo Resumo
55. Peters SA, Huxley RR, Sattar N, et al. Sex differences in the excess risk of cardiovascular diseases associated with type 2 diabetes: potential explanations and clinical implications. Curr Cardiovasc Risk Rep. 2015;9(7):36.Texto completo Resumo
56. Connelly PJ, Marie Freel E, Perry C, et al. Gender-affirming hormone therapy, vascular health and cardiovascular disease in transgender adults. Hypertension. 2019 Dec;74(6):1266-74.Texto completo Resumo
57. Mehta LS, Velarde GP, Lewey J, et al. Cardiovascular disease risk factors in women: the impact of race and ethnicity: a scientific statement from the American Heart Association. Circulation. 2023 May 9;147(19):1471-87.Texto completo Resumo
58. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia. 2019 Jun;62(6):905-14.Texto completo Resumo
59. Xie W, Wang Y, Xiao S, et al. Association of gestational diabetes mellitus with overall and type specific cardiovascular and cerebrovascular diseases: systematic review and meta-analysis. BMJ. 2022 Sep 21;378:e070244.Texto completo Resumo
60. Mechanick JI, Farkouh ME, Newman JD, et al. Cardiometabolic-based chronic disease, addressing knowledge and clinical practice gaps: JACC state-of-the-art review. J Am Coll Cardiol. 2020 Feb 11;75(5):539-55.Texto completo Resumo
61. Rosenzweig JL, Bakris GL, Berglund LF, et al. Primary prevention of ASCVD and T2DM in patients at metabolic risk: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019 Sep 1;104(9):3939-85.Texto completo Resumo
62. Choi YJ, Han KD, Choi EK, et al. Alcohol abstinence and the risk of atrial fibrillation in patients with newly diagnosed type 2 diabetes mellitus: a nationwide population-based study. Diabetes Care. 2021 Jun;44(6):1393-401.Texto completo Resumo
63. Bowman L, Mafham M, Wallendszus K, et al; ASCEND Study Collaborative Group. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018 Aug 26;379(16):1529-39.Texto completo Resumo
64. Patel NJ, Baliga RR. Role of aspirin for primary prevention in persons with diabetes mellitus and in the elderly. Curr Cardiol Rep. 2020 May 29;22(7):48. Resumo
65. US Preventive Services Task Force. Aspirin use to prevent cardiovascular disease: preventive medication. April 2022 [internet publication].Texto completo
66. Zhao B, Zeng L, Zhao J, et al. Association of magnesium intake with type 2 diabetes and total stroke: an updated systematic review and meta-analysis. BMJ Open. 2020 Mar 19;10(3):e032240.Texto completo Resumo
67. Gerstein HC, Yusuf S, Bosch J, et al; DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet. 2006 Sep 23;368(9541):1096-105. Resumo
68. Holman RR, Haffner SM, McMurray JJ, et al; NAVIGATOR Study Group. Effect of nateglinide on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010 Apr 22;362(16):1463-76.Texto completo Resumo
69. McMurray JJ, Holman RR, Haffner SM, et al; NAVIGATOR Study Group. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010 Apr 22;362(16):1477-90.Texto completo Resumo
70. Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (canagliflozin cardiovascular assessment study). Circulation. 2018 Jan 23;137(4):323-34.Texto completo Resumo
71. Rossing P, Inzucchi SE, Vart P, et al. Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials. Lancet Diabetes Endocrinol. 2022 Jan;10(1):24-34. Resumo
72. Nazarzadeh M, Bidel Z, Canoy D, et al. Blood pressure lowering and risk of new-onset type 2 diabetes: an individual participant data meta-analysis. Lancet. 2021 Nov 13;398(10313):1803-10.Texto completo Resumo
73. Yahyavi SK, Snorgaard O, Knop FK, et al. Prediabetes defined by first measured HbA1c predicts higher cardiovascular risk compared with HbA1c in the diabetes range: a cohort study of nationwide registries. Diabetes Care. 2021 Dec;44(12):2767-74. Resumo
74. Fleg JL, Forman DE, Berra K, et al; American Heart Association. Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association. Circulation. 2013 Nov 26;128(22):2422-46.Texto completo Resumo
75. Klein L, Gheorghiade M. Management of the patient with diabetes mellitus and myocardial infarction: clinical trials update. Am J Med. 2004 Mar 8;116(suppl 5A):47-63S. Resumo
76. Stevens RJ, Coleman RL, Adler AI, et al. Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. Diabetes Care. 2004 Jan;27(1):201-7.Texto completo Resumo
77. Giraldez RR, Clare RM, Lopes RD, et al. Prevalence and clinical outcomes of undiagnosed diabetes mellitus and prediabetes among patients with high-risk non-ST-segment elevation acute coronary syndrome. Am Heart J. 2013 Jun;165(6):918-25. Resumo
78. Sacre JW, Magliano DJ, Shaw JE. Incidence of hospitalization for heart failure relative to major atherosclerotic events in type 2 diabetes: a meta-analysis of cardiovascular outcomes trials. Diabetes Care. 2020 Oct;43(10):2614-23.Texto completo Resumo
79. Wamil M, Coleman RL, Adler AI, et al. Increased risk of incident heart failure and death is associated with insulin resistance in people with newly diagnosed type 2 diabetes: UKPDS 89. Diabetes Care. 2021 Aug;44(8):1877-84.Texto completo Resumo
80. Goraya TY, Leibson CL, Palumbo PJ, et al. Coronary atherosclerosis in diabetes mellitus: a population-based autopsy study. J Am Coll Cardiol. 2002 Sep 4;40(5):946-53. Resumo
81. Kip KE, Faxon DP, Detre KM, et al. Coronary angioplasty in diabetic patients. Circulation. 1996 Oct 15;94(8):1818-25.Texto completo Resumo
82. Chen R, Ovbiagele B, Feng W. Diabetes and stroke: epidemiology, pathophysiology, pharmaceuticals and outcomes. Am J Med Sci. 2016 Apr;351(4):380-6.Texto completo Resumo
83. Idris I, Thomson GA, Sharma JC. Diabetes mellitus and stroke. Int J Clin Pract. 2006 Jan;60(1):48-56. Resumo
84. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2017 Mar 21;69(11):e71-126.Texto completo Resumo
85. American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care. 2003 Dec;26(12):3333-41.Texto completo Resumo
86. Scott RA, Bridgewater SG, Ashton HA. Randomized clinical trial of screening for abdominal aortic aneurysm in women. Br J Surg. 2002 Mar;89(3):283-5.Texto completo Resumo
87. Golledge J, Clancy P, Jamrozik K, et al. Obesity, adipokines, and abdominal aortic aneurysm. Health in Men study. Circulation. 2007 Nov 13;116(20):2275-9.Texto completo Resumo
88. Dattani N, Sayers RD, Bown MJ. Diabetes mellitus and abdominal aortic aneurysms: a review of the mechanisms underlying the negative relationship. Diab Vasc Dis Res. 2018 Sep;15(5):367-74.Texto completo Resumo
89. Golledge J, Karan M, Moran CS, et al. Reduced expansion rate of abdominal aortic aneurysms in patients with diabetes may be related to aberrant monocyte-matrix interactions. Eur Heart J. 2008 Mar;29(5):665-72. Resumo
90. Smith SC Jr, Greenland P, Grundy SM. AHA Conference Proceedings. Prevention conference V. Beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. American Heart Association. Circulation. 2000 Jan 4-11;101(1):111-6.Texto completo Resumo
91. Creager MA. Medical management of peripheral arterial disease. Cardiol Rev. 2001 Jul-Aug;9(4):238-45. Resumo
92. Berman DS, Hachamovitch R, Shaw LJ, et al. Roles of nuclear cardiology, cardiac computed tomography, and cardiac magnetic resonance: noninvasive risk stratification and a conceptual framework for the selection of noninvasive imaging tests in patients with known or suspected coronary artery disease. J Nucl Med. 2006 Jul;47(7):1107-18.Texto completo Resumo
93. Lee DP, Fearon WF, Froelicher VF. Clinical utility of the exercise ECG in patients with diabetes and chest pain. Chest. 2001 May;119(5):1576-81. Resumo
94. Fletcher GF, Ades PA, Kligfield P, et al. Exercise standards for testing and training: a scientific statement from the American Heart Association. Circulation. 2013 Aug 20;128(8):873-934.Texto completo Resumo
95. Gulati M, Levy PD, Mukherjee D, et al. 2021 AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR guideline for the evaluation and diagnosis of chest pain: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2021 Nov 30;144(22):e368-454.Texto completo Resumo
96. Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article - a report of the American College of Cardiology/American Heart Association task force on practice guidelines (committee to update the 1997 exercise testing guidelines). J Am Coll Cardiol. 2002 Oct 16;40(8):1531-40.Texto completo Resumo
97. Patel AR, Salerno M, Kwong RY, et al. Stress cardiac magnetic resonance myocardial perfusion imaging: JACC review topic of the week. J Am Coll Cardiol. 2021 Oct 19;78(16):1655-68. Resumo
98. Bax JJ, Young LH, Frye RL, et al. Screening for coronary artery disease in patients with diabetes. Diabetes Care. 2007 Oct;30(10):2729-36.Texto completo Resumo
99. Muhlestein JB, Lappé DL, Lima JA, et al. Effect of screening for coronary artery disease using CT angiography on mortality and cardiac events in high-risk patients with diabetes: the FACTOR-64 randomized clinical trial. JAMA. 2014 Dec 3;312(21):2234-43. Resumo
100. Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. Circulation. 2019 Jun 18;139(25):e1082-143.Texto completo Resumo
101. Pop-Busui R, Januzzi JL, Bruemmer D, et al. Heart failure: an underappreciated complication of diabetes – a consensus report of the American Diabetes Association. Diabetes Care. 2022 Jul 7;45(7):1670-90.Texto completo Resumo
102. Kumar R, Patel CD, Marwah A, et al. Detection of coronary artery disease by stress thallium scintigraphy in diabetic patients. Nucl Med Commun. 2001 Mar;22(3):287-9. Resumo
103. Paillole C, Ruiz J, Juliard JM, et al. Detection of coronary artery disease in diabetic patients. Diabetologia. 1995 Jun;38(6):726-31. Resumo
104. Scanlon PJ, Faxon DP, Audet AM, et al. ACC/AHA guidelines for coronary angiography: executive summary and recommendations. Circulation. 1999 May 4;99(17):2345-57.Texto completo Resumo
105. Brott TG, Halperin JL, Abbara S, et al. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease. J Am Coll Cardiol. 2011 Feb 22;57(8):e16-94.Texto completo Resumo
106. Emberson J, Bennett D, Link E, et al; Heart Protection Study Collaborative Group. C-reactive protein concentration and the vascular benefits of statin therapy: an analysis of 20,536 patients in the Heart Protection Study. Lancet. 2011 Feb 5;377(9764):469-76.Texto completo Resumo
107. American Diabetes Association. Standards of medical care in diabetes - 2022. Diabetes Care. 2022 Jan;45(Suppl 1):S1-264.Texto completo
108. US Preventive Services Task Force. Prediabetes and type 2 diabetes: screening. August 2021 [internet publication].Texto completo
109. Di Angelantonio E, Gao P, Khan H, et al; Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014 Mar 26;311(12):1225-33.Texto completo Resumo
110. Lièvre MM, Moulin P, Thivolet C, et al. Detection of silent myocardial ischemia in asymptomatic patients with diabetes: results of a randomized trial and meta-analysis assessing the effectiveness of systematic screening. Trials. 2011 Jan 26;12:23.Texto completo Resumo
111. Rados DV, Pinto LC, Leitão CB, et al. Screening for coronary artery disease in patients with type 2 diabetes: a meta-analysis and trial sequential analysis. BMJ Open. 2017 May 9;7(5):e015089.Texto completo Resumo
112. Rawshani A, Rawshani A, Franzén S, et al. Risk factors, mortality, and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2018 Aug 16;379(7):633-44.Texto completo Resumo
113. Arnold SV, de Lemos JA, Rosenson RS, et al; GOULD Investigators. Use of guideline-recommended risk-reduction strategies among patients with diabetes and atherosclerotic cardiovascular disease. Circulation. 2019 Aug 13;140(7):618-20.Texto completo Resumo
114. Evert AB, Dennison M, Gardner CD, et al. Nutrition therapy for adults with diabetes or prediabetes: a consensus report. Diabetes Care. 2019 Apr 18;42(5):731-54.Texto completo Resumo
115. Wing RR; Look AHEAD Research Group. Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med. 2010 Sep 27;170(17):1566-75.Texto completo Resumo
116. Elhayany A, Lustman A, Abel R, et al. A low carbohydrate Mediterranean diet improves cardiovascular risk factors and diabetes control among overweight patients with type 2 diabetes mellitus: a 1-year prospective randomized intervention study. Diabetes Obes Metab. 2010 Mar;12(3):204-9. Resumo
117. Wheeler ML, Dunbar SA, Jaacks LM, et al. Macronutrients, food groups, and eating patterns in the management of diabetes: a systematic review of the literature, 2010. Diabetes Care. 2012 Feb;35(2):434-45.Texto completo Resumo
118. Esposito K, Maiorino MI, Ciotola M, et al. Effects of a Mediterranean-style diet on the need for antihyperglycemic drug therapy in patients with newly diagnosed type 2 diabetes: a randomized trial. Ann Intern Med. 2009 Sep 1;151(5):306-14. Resumo
119. Azadbakht L, Fard NR, Karimi M, et al. Effects of the Dietary Approaches to Stop Hypertension (DASH) eating plan on cardiovascular risks among type 2 diabetic patients: a randomized crossover clinical trial. Diabetes Care. 2011 Jan;34(1):55-7.Texto completo Resumo
120. Barnard ND, Cohen J, Jenkins DJ, et al. A low-fat vegan diet improves glycemic control and cardiovascular risk factors in a randomized clinical trial in individuals with type 2 diabetes. Diabetes Care. 2006 Aug;29(8):1777-83.Texto completo Resumo
121. Schwab U, Reynolds AN, Sallinen T, et al. Dietary fat intakes and cardiovascular disease risk in adults with type 2 diabetes: a systematic review and meta-analysis. Eur J Nutr. 2021 Sep;60(6):3355-63. Resumo
122. Noronha JC, Nishi SK, Braunstein CR, et al. The effect of liquid meal replacements on cardiometabolic risk factors in overweight/obese individuals with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Diabetes Care. 2019 May;42(5):767-76.Texto completo Resumo
123. Batty GD, Shipley MJ, Marmot M, et al. Physical activity and cause-specific mortality in men with type 2 diabetes/impaired glucose tolerance: evidence from the Whitehall study. Diabet Med. 2002 Jul;19(7):580-8. Resumo
124. Wormgoor SG, Dalleck LC, Zinn C, et al. Effects of high-intensity interval training on people living with type 2 diabetes: a narrative review. Can J Diabetes. 2017 Oct;41(5):536-47. Resumo
125. Tikkanen-Dolenc H, Wadén J, Forsblom C, et al. Physical activity reduces risk of premature mortality in patients with type 1 diabetes with and without kidney disease. Diabetes Care. 2017 Dec;40(12):1727-32. Resumo
126. Kemps H, Kränkel N, Dörr M, et al. Exercise training for patients with type 2 diabetes and cardiovascular disease: what to pursue and how to do it – position paper of the European Association of Preventive Cardiology (EAPC). Eur J Prev Cardiol. 2019 May;26(7):709-27.Texto completo Resumo
127. Palmer SC, Tendal B, Mustafa RA, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2021 Jan 13;372:m4573.Texto completo Resumo
128. Hussain S, Khan MS, Jamali MC, et al. Impact of bariatric surgery in reducing macrovascular complications in severely obese T2DM patients. Obes Surg. 2021 May;31(5):1929-36. Resumo
129. Cohen R, Sforza NS, Clemente RG. Impact of metabolic surgery on type 2 diabetes mellitus, cardiovascular risk factors, and mortality: a review. Curr Hypertens Rev. 2021;17(2):159-69. Resumo
130. Koegelenberg CF, Noor F, Bateman ED, et al. Efficacy of varenicline combined with nicotine replacement therapy vs varenicline alone for smoking cessation: a randomized clinical trial. JAMA. 2014 Jul;312(2):155-61.Texto completo Resumo
131. Cavero-Redondo I, Peleteiro B, Álvarez-Bueno C, et al. Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis. BMJ Open. 2017 Jul 31;7(7):e015949.Texto completo Resumo
132. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009 Jan 8;360(2):129-39.Texto completo Resumo
133. Reaven PD, Emanuele NV, Wiitala WL, et al; VADT Investigators. Intensive glucose control in patients with type 2 diabetes - 15-year follow-up. N Engl J Med. 2019 Jun 6;380(23):2215-24. Resumo
134. ACCORD Study Group. Nine-year effects of 3.7 years of intensive glycemic control on cardiovascular outcomes. Diabetes Care. 2016 Jan 28;39(5):701-8.Texto completo Resumo
135. Zoungas S, Chalmers J, Ninomiya T, et al; ADVANCE Collaborative Group. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2011 Dec 21;55(3):636-43.Texto completo Resumo
136. Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: the DCCT/EDIC Study 30-year follow-up. Diabetes Care. 2016 Feb 9;39(5):686-93.Texto completo Resumo
137. Hayward RA, Reaven PD, Wiitala WL, et al; VADT Investigators. Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015 Jun 4;372(23):2197-206.Texto completo Resumo
138. Gerstein HC, Miller ME, Ismail-Beigi F, et al; ACCORD Study Group. Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial. Lancet. 2014 Nov 29;384(9958):1936-41.Texto completo Resumo
139. Holman R, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1577-89.Texto completo Resumo
140. Gerstein HC, Miller ME, et al; Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 Jun 6;358(24):2545-59.Texto completo Resumo
141. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-86.Texto completo Resumo
142. Das SR, Everett BM, Birtcher KK, et al. 2020 Expert consensus decision pathway on novel therapies for cardiovascular risk reduction in patients with type 2 diabetes: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2020 Sep 1;76(9):1117-45.Texto completo Resumo
143. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. Circulation. 2022 May 3;145(18):e895-1032.Texto completo Resumo
144. Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 2021 Oct;9(10):653-62. Resumo
145. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2018 Nov 10;393(10166):31-9. Resumo
146. Zerovnik S, Kos M, Locatelli I. Cardiovascular morbidity and mortality in patients with type 2 diabetes using novel antidiabetic medicines as add-on therapy: an observational real-world study. BMJ Open. 2021 Sep 13;11(9):e051549.Texto completo Resumo
147. Braunwald E. Gliflozins in the management of cardiovascular disease. N Engl J Med. 2022 May 26;386(21):2024-34. Resumo
148. McDonagh TA, Metra M, Adamo M, et al. 2023 Focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023 Oct 1;44(37):3627-39.Texto completo
149. Neuen BL, Oshima M, Agarwal R, et al. Sodium-glucose cotransporter 2 inhibitors and risk of hyperkalemia in people with type 2 diabetes: a meta-analysis of individual participant data from randomized, controlled trials. Circulation. 2022 May 10;145(19):1460-70.Texto completo Resumo
150. Kanie T, Mizuno A, Takaoka Y, et al. Dipeptidyl peptidase-4 inhibitors, glucagon-like peptide 1 receptor agonists and sodium-glucose co-transporter-2 inhibitors for people with cardiovascular disease: a network meta-analysis. Cochrane Database Syst Rev. 2021 Oct 25;10(10):CD013650.Texto completo Resumo
151. Jhalani NB. Clinical Considerations for use of SGLT2 inhibitor therapy in patients with heart failure and reduced ejection fraction: a review. Adv Ther. 2022 Aug;39(8):3472-87.Texto completo Resumo
152. Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021 Oct 14;385(16):1451-61.Texto completo Resumo
153. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022 Sep 22;387(12):1089-98.Texto completo Resumo
154. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019 Jul 13;394(10193):121-30. Resumo
155. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019 Aug 29;381(9):841-51.Texto completo Resumo
156. Westerink J, Matthiessen KS, Nuhoho S, et al. Estimated life-years gained free of new or recurrent major cardiovascular events with the addition of semaglutide to standard of care in people with type 2 diabetes and high cardiovascular risk. Diabetes Care. 2022 May 1;45(5):1211-8.Texto completo Resumo
157. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019 Jan 24;380(4):347-57.Texto completo Resumo
158. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019 Nov 21;381(21):1995-2008.Texto completo Resumo
159. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019 Jun 13;380(24):2295-306.Texto completo Resumo
160. Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups. Circulation. 2019 Aug 27;140(9):739-50.Texto completo Resumo
161. Inzucchi SE, Kosiborod M, Fitchett D, et al. Improvement in cardiovascular outcomes with empagliflozin is independent of glycemic control. Circulation. 2018 Oct 23;138(17):1904-7.Texto completo Resumo
162. European Medicines Agency. SGLT2 inhibitors: information on potential risk of toe amputation to be included in prescribing information. February 2017 [internet publication].Texto completo
163. US Food and Drug Administration. FDA removes boxed warning about risk of leg and foot amputations for the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). August 2020 [internet publication]Texto completo
164. US Food and Drug Administration. FDA drug safety communication: FDA warns about rare occurrences of a serious infection of the genital area with SGLT2 inhibitors for diabetes. August 2018 [internet publication].Texto completo
165. Medicines and Healthcare products Regulatory Agency. SGLT2 inhibitors: reports of Fournier’s gangrene (necrotising fasciitis of the genitalia or perineum). February 2019 [internet publication].Texto completo
166. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007 Jun 14;356(24):2457-71.Texto completo Resumo
167. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007 Sep 12;298(10):1189-95. Resumo
168. Kaul S, Bolger AF, Herrington D, et al. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation. 2010 Apr 27;121(16):1868-77.Texto completo Resumo
169. Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes: an interim analysis. N Engl J Med. 2007 Jul 5;357(1):28-38.Texto completo Resumo
170. Nissen SE, Wolski K. Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med. 2010 Jul 26;170(14):1191-201. Resumo
171. Psaty BM, Furberg CD. The record on rosiglitazone and the risk of myocardial infarction. N Engl J Med. 2007 Jul 5;357(1):67-9.Texto completo Resumo
172. Liao HW, Saver JL, Wu YL, et al. Pioglitazone and cardiovascular outcomes in patients with insulin resistance, pre-diabetes and type 2 diabetes: a systematic review and meta-analysis. BMJ Open. 2017 Jan 5;7(1):e013927.Texto completo Resumo
173. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. Circulation. 2009 Apr 14;119(14):e391-479.Texto completo Resumo
174. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ. 2009 Mar 24;180(8):821-7.Texto completo Resumo
175. Sathya B, Davis R, Taveira T, et al. Intensity of peri-operative glycemic control and postoperative outcomes in patients with diabetes: a meta-analysis. Diabetes Res Clin Pract. 2013 Jun 6;102(1):8-15. Resumo
176. de Mulder M, Umans VA, Cornel JH, et al. Intensive glucose regulation in hyperglycemic acute coronary syndrome: results of the randomized BIOMarker study to identify the acute risk of a coronary syndrome-2 (BIOMArCS-2) glucose trial. JAMA Intern Med. 2013 Nov 11;173(20):1896-904.Texto completo Resumo
177. Finfer S, Chittock DR, Su SY, et al; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97.Texto completo Resumo
178. Inzucchi SE, Siegel MD. Glucose control in the ICU: how tight is too tight? N Engl J Med. 2009 Mar 26;360(13):1346-9. Resumo
179. Kirdemir P, Yildirim V, Kiris I, et al. Does continuous insulin therapy reduce postoperative supraventricular tachycardia incidence after coronary artery bypass operations in diabetic patients? J Cardiothorac Vasc Anesth. 2008 Jun;22(3):383-7. Resumo
180. Lazar HL, Chipkin SR, Fitzgerald CA, et al. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation. 2004 Mar 30;109(12):1497-502.Texto completo Resumo
181. Wang YY, Hu SF, Ying HM, et al. Postoperative tight glycemic control significantly reduces postoperative infection rates in patients undergoing surgery: a meta-analysis. BMC Endocr Disord. 2018 Jun 22;18(1):42.Texto completo Resumo
182. Shi S, Gouskova N, Najafzadeh M, et al. Intensive versus standard blood pressure control in type 2 diabetes: a restricted mean survival time analysis of a randomised controlled trial. BMJ Open. 2021 Sep 13;11(9):e050335.Texto completo Resumo
183. Zhang W, Zhang S, Deng Y, et al. Trial of intensive blood-pressure control in older patients with hypertension. N Engl J Med. 2021 Sep 30;385(14):1268-79.Texto completo Resumo
184. Brouwer TF, Vehmeijer JT, Kalkman DN, et al. Intensive blood pressure lowering in patients with and patients without type 2 diabetes: a pooled analysis from two randomized trials. Diabetes Care. 2018 Jun;41(6):1142-8. Resumo
185. Palmer SC, Mavridis D, Navarese E, et al. Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis. Lancet. 2015 May 23;385(9982):2047-56. Resumo
186. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf. 2005;28(7):601-31. Resumo
187. Cheng J, Zhang W, Zhang X, et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med. 2014 May;174(5):773-85.Texto completo Resumo
188. Liakos CI, Papadopoulos DP, Sanidas EA, et al. Blood pressure-lowering effect of newer antihyperglycemic agents (SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors). Am J Cardiovasc Drugs. 2021 Mar;21(2):123-37. Resumo
189. Arnold SV, Bhatt DL, Barsness GW, et al. Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association. Circulation. 2020 May 12;141(19):e779-806.Texto completo Resumo
190. Carnovale C, Gringeri M, Battini V, et al. Beta-blocker-associated hypoglycaemia: new insights from a real-world pharmacovigilance study. Br J Clin Pharmacol. 2021 Aug;87(8):3320-31.Texto completo Resumo
191. Wing RR, Bolin P, Brancati FL, et al; Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013 Jul 11;369(2):145-54.Texto completo Resumo
192. Farkouh ME, Godoy LC, Brooks MM, et al. Influence of LDL-cholesterol lowering on cardiovascular outcomes in patients with diabetes mellitus undergoing coronary revascularization. J Am Coll Cardiol. 2020 Nov 10;76(19):2197-207.Texto completo Resumo
193. Giugliano RP, Cannon CP, Blazing MA, et al; IMPROVE-IT Investigators. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation. 2017 Dec 20;137(15):1571-82.Texto completo Resumo
194. Bhatt DL, Steg PG, Miller M, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22.Texto completo Resumo
195. Doi T, Langsted A, Nordestgaard BG. A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs. Eur Heart J. 2021 Dec 14;42(47):4807-17.Texto completo Resumo
196. Olshansky B, Chung MK, Budoff MJ, et al. Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies. Eur Heart J Suppl. 2020 Oct;22(suppl j):J34-J48.Texto completo Resumo
197. Bosch J, Gerstein HC, Dagenais GR, et al; ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012 Jul 26;367(4):309-18.Texto completo Resumo
198. Ajjan RA, Kietsiriroje N, Badimon L, et al. Antithrombotic therapy in diabetes: which, when, and for how long? Eur Heart J. 2021 Jun 14;42(23):2235-59.Texto completo Resumo
199. Pistrosch F, Matschke JB, Schipp D, et al. Rivaroxaban compared with low-dose aspirin in individuals with type 2 diabetes and high cardiovascular risk: a randomised trial to assess effects on endothelial function, platelet activation and vascular biomarkers. Diabetologia. 2021 Dec;64(12):2701-12.Texto completo Resumo
200. Writing Committee Members; Lawton JS, Tamis-Holland JE, Bangalore S, et al. 2021 ACC/AHA/SCAI guideline for coronary artery revascularization: a report of the American College of Cardiology/American Heart Association joint committee on clinical practice guidelines. J Am Coll Cardiol. 2022 Jan 18;79(2):e21-129.Texto completo Resumo
201. Angiolillo DJ, Bhatt DL, Cannon CP, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention: a North American perspective – 2021 update. Circulation. 2021 Feb 9;143(6):583-96.Texto completo Resumo
202. Marfella R, Sasso FC, Siniscalchi M, et al. Peri-procedural tight glycemic control during early percutaneous coronary intervention is associated with a lower rate of in-stent restenosis in patients with acute ST-elevation myocardial infarction. J Clin Endocrinol Metab. 2012 Aug;97(8):2862-71. Resumo
203. Grines C, Patel A, Zijlstra F, et al. Primary coronary angioplasty compared with intravenous thrombolytic therapy for acute myocardial infarction: six-month follow up and analysis of individual patient data from randomized trials. Am Heart J. 2003 Jan;145(1):47-57. Resumo
204. Collet JP, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021 Apr 7;42(14):1289-367.Texto completo Resumo
205. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation. 2001 Dec 4;104(23):2767-71.Texto completo Resumo
206. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J. 2019 Jan 7;40(2):87-165.Texto completo Resumo
207. Patel MR, Calhoon JH, Dehmer GJ, et al. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease: a report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2017 May 2;69(17):2212-41.Texto completo Resumo
208. Farkouh ME, Domanski M, Dangas GD, et al; FREEDOM Follow-On Study Investigators. Long-term survival following multivessel revascularization in patients with diabetes: the FREEDOM follow-on study. J Am Coll Cardiol. 2019 Feb 19;73(6):629-38. Resumo
209. Wang R, Serruys PW, Gao C, et al. Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. Eur Heart J. 2021 Dec 28;43(1):56-67.Texto completo Resumo
210. Stone GW, Sabik JF, Serruys PW, et al. Everolimus-eluting stents or bypass surgery for left main coronary artery disease. N Engl J Med. 2016 Dec 8;375(23):2223-35. Resumo
211. Kapur A, Hall RJ, Malik IS, et al. Randomized comparison of percutaneous coronary intervention with coronary artery bypass grafting in diabetic patients: 1-year results of the CARDia (Coronary Artery Revascularization in Diabetes) trial. J Am Coll Cardiol. 2010 Feb 2;55(5):432-40. Resumo
212. Mohr FW, Morice MC, Kappetein AP, et al. Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. Lancet. 2013 Feb 23;381(9867):629-38. Resumo
213. Kappetein AP, Head SJ, Morice MC, et al; SYNTAX Investigators. Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. Eur J Cardiothorac Surg. 2013 May;43(5):1006-13.Texto completo Resumo
214. Farkouh ME, Domanski M, Sleeper LA, et al; FREEDOM Trial Investigators. Strategies for multivessel revascularization in patients with diabetes. N Engl J Med. 2012 Dec 20;367(25):2375-84.Texto completo Resumo
215. Bypass Angioplasty Revascularization Investigators. Seven-year outcome in the Bypass Angioplasty Revascularization Investigation (BARI) by treatment and diabetic status. J Am Coll Cardiol. 2000 Apr;35(5):1122-9. Resumo
216. BARI Investigators. The final 10-year follow-up results from the BARI randomized trial. J Am Coll Cardiol. 2007 Apr 2;49(15):1600-6.Texto completo Resumo
217. Flaherty JD, Davidson CJ. Diabetes and coronary revascularization. JAMA. 2005 Mar 23;293(12):1501-8.Texto completo Resumo
218. Berry C, Tardif JC, Bourassa MG. Coronary heart disease in patients with diabetes: part II: recent advances in coronary revascularization. J Am Coll Cardiol. 2007 Feb 13;49(6):643-56. Resumo
219. Banning AP, Westaby S, Morice MC, et al. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents. J Am Coll Cardiol. 2010 Mar 16;55(11):1067-75. Resumo
220. Maresta A, Varani E, Balducci M, et al. Comparison of effectiveness and safety of sirolimus-eluting stents versus bare-metal stents in patients with diabetes mellitus (from the Italian Multicenter Randomized DESSERT Study). Am J Cardiol. 2008 Jun 1;101(11):1560-6. Resumo
221. Mahmud E, Bromberg-Marin G, Palakodeti V, et al. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis. J Am Coll Cardiol. 2008 Jun 24;51(25):2385-95. Resumo
222. Garg P, Normand SL, Silbaugh TS, et al. Drug-eluting or bare-metal stenting in patients with diabetes mellitus: results from the Massachusetts Data Analysis Center Registry. Circulation. 2008 Nov 25;118(22):2277-85. Resumo
223. Frye RL, August P, Brooks MM, et al; BARI 2D Study Group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009 Jun 11;360(24):2503-15.Texto completo Resumo
224. De Luca G, Dirksen MT, Spaulding C, et al; DESERT Cooperation. Meta-analysis comparing efficacy and safety of first generation drug-eluting stents to bare-metal stents in patients with diabetes mellitus undergoing primary percutaneous coronary intervention. Am J Cardiol. 2013 May 1;111(9):1295-304. Resumo
225. Newman JD, Anthopolos R, Mancini GBJ, et al. Outcomes of participants with diabetes in the ISCHEMIA trials. Circulation. 2021 Oct 26;144(17):1380-95.Texto completo Resumo
226. Amsterdam EA, Wenger NK, Brindis RG, et al; ACC/AHA Task Force Members. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014 Dec 23;130(25):e344-426.Texto completo Resumo
227. Boden WE, O'Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med. 2007 Apr 12;356(15):1503-16.Texto completo Resumo
228. Maron DJ, Hochman JS, Reynolds HR, et al. Initial invasive or conservative strategy for stable coronary disease. N Engl J Med. 2020 Apr 9;382(15):1395-407.Texto completo Resumo
229. Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. N Engl J Med. 2006 Nov 2;355(18):1903-11. Resumo
230. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. N Engl J Med. 2006 Feb 2;354(5):449-61.Texto completo Resumo
231. Squizzato A, Bellesini M, Takeda A, et al. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Cochrane Database Syst Rev. 2017 Dec 14;(12):CD005158.Texto completo Resumo
232. Wright AK, Carr MJ, Kontopantelis E, et al. Primary prevention of cardiovascular and heart failure events with SGLT2 inhibitors, GLP-1 receptor agonists, and their combination in type 2 diabetes. Diabetes Care. 2022 Apr 1;45(4):909-18. Resumo
233. Kato ET, Silverman MG, Mosenzon O, et al. Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus. Circulation. 2019 May 28;139(22):2528-36.Texto completo Resumo
234. Cefalo CMA, Cinti F, Moffa S, et al. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives. Cardiovasc Diabetol. 2019 Feb 28;18(1):20.Texto completo Resumo
235. Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021 Jan 14;384(2):129-39.Texto completo Resumo
236. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021 Jan 14;384(2):117-28.Texto completo Resumo
237. Bakris GL, Agarwal R, Anker SD, et al. Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med. 2020 Dec 3;383(23):2219-29.Texto completo Resumo
238. Pitt B, Filippatos G, Agarwal R, et al. Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med. 2021 Dec 9;385(24):2252-63.Texto completo Resumo
239. Willard FS, Douros JD, Gabe MB, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020 Sep 3;5(17):e140532.Texto completo Resumo
240. Rosenstock J, Wysham C, Frías JP, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021 Jul 10;398(10295):143-55. Resumo
241. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. 2021 Aug 5;385(6):503-15. Resumo
242. Ludvik B, Giorgino F, Jódar E, et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021 Aug 14;398(10300):583-98. Resumo
243. Del Prato S, Kahn SE, Pavo I, et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet. 2021 Nov 13;398(10313):1811-24. Resumo
244. Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022 Feb 8;327(6):534-45.Texto completo Resumo
245. Yoon KH, Kang J, Kwon SC, et al. Pharmacokinetic and dose-finding studies on efpeglenatide in patients with type 2 diabetes. Diabetes Obes Metab. 2020 Aug;22(8):1292-301.Texto completo Resumo
246. Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med. 2021 Sep 2;385(10):896-907.Texto completo Resumo
247. Lam CSP, Ramasundarahettige C, Branch KRH, et al. Efpeglenatide and clinical outcomes with and without concomitant sodium-glucose cotransporter-2 inhibition use in type 2 diabetes: exploratory analysis of the AMPLITUDE-O trial. Circulation. 2022 Feb 22;145(8):565-74.Texto completo Resumo
248. Pratley RE, Jacob S, Baek S, et al. Efficacy and safety of efpeglenatide in key patient subgroups from the BALANCE randomized trial, stratified by pre-diabetes status, BMI, and age at baseline. BMJ Open Diabetes Res Care. 2022 Jan;10(1):e002207.Texto completo Resumo
249. Dai L, Zuo Y, You Q, et al. Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol. 2021 Jul 23;28(8):825-33.Texto completo Resumo
250. Nissen SE, Lincoff AM, Brennan D, et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N Engl J Med. 2023 Apr 13;388(15):1353-64. Resumo
251. Kerola AM, Juonala M, Palomäki A, et al. Case fatality of patients with type 1 diabetes after myocardial infarction. Diabetes Care. 2022 Jul 7;45(7):1657-65.Texto completo Resumo
252. Dunlay SM, Givertz MM, Aguilar D, et al. Type 2 diabetes mellitus and heart failure: a scientific statement from the American Heart Association and the Heart Failure Society of America. Circulation. 2019 Aug 13;140(7):e294-324.Texto completo Resumo
253. MacDonald MR, Petrie MC, Varvani F, et al. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur Heart J. 2008 Jun;29(11):1377-85.Texto completo Resumo
254. Kamalesh M. Heart failure in diabetes and related conditions. J Card Fail. 2007 Dec;13(10):861-73. Resumo
255. Bruce DG, Davis WA, Casey GP, et al. Predictors of cognitive impairment and dementia in older people with diabetes. Diabetologia. 2008 Feb;51(2):241-8. Resumo
256. Pagidipati NJ, Navar AM, Pieper KS, et al. Secondary prevention of cardiovascular disease in patients with type 2 diabetes mellitus: international insights from the TECOS trial (trial evaluating cardiovascular outcomes with sitagliptin). Circulation. 2017 Sep 26;136(13):1193-203. Resumo
257. Rangaswami J, Bhalla V, de Boer IH, et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: a scientific statement from the American Heart Association. Circulation. 2020 Oct 27;142(17):e265-86.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal